| Project Detail |
DISEASE
Malaria
TYPE
Prevention
LEAD GRANTEE
Jhpiego
GRANT FOCUS
Provide pregnant women with intermittent doses of sulfadoxine-pyramethamine, a medicine that prevents malaria, and gather data on delivery through community health workers.
STATUS
Current
TIME FRAME
2017-2022
GRANT VALUE
US$ 49,653,329
DISBURSEMENTS
As of 5.11.2018
US$ 13,187,187
Averting stillbirths, maternal deaths and other complications of malaria, a totally preventable disease.
Challenges
In malaria-endemic areas, as much as 10 percent of maternal deaths are caused by malaria in pregnancy.
Solutions
This project, known as TIPTOP, is working to break down barriers between pregnant women and the malaria medicines they need.
“Preventing malaria in pregnancy and reducing malaria-related deaths is achievable, and this partnership will go a long way toward reaching those goals.”
DR. LESLIE MANCUSO, JHPIEGO CEO AND PRESIDENT
Progress so far
In the first half of 2018, Jhpiego and its partners began a community-based effort to provide IPTp, working in collaboration with the ministries of health of the four project countries. The TIPTOP project has also made substantial progress in collecting data, developing training materials, finalizing research protocols and preparing facilities for IPTp delivery. TIPTOP is encouraging key malaria and reproductive health stakeholders to integrate IPTp into their programs and to work toward making it a priority in country budgets.
The impact we are seeking
The project intends to make anti-malaria prevention a standard part of community-based prenatal care in countries where the disease is prevalent. Four sub-Saharan African countries are participating in the five-year project, but TIPTOP’s longer-term goal is to create a model that can be used in other malaria-endemic countries. The project will work to increase demand for the drug involved—sulfadoxine pyrimethamine. |
